Takeda Pharmaceutical Co. (NYSE:TAK) Shares Bought by Cetera Investment Advisers

Cetera Investment Advisers raised its stake in Takeda Pharmaceutical Co. (NYSE:TAK) by 26.9% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 75,237 shares of the company’s stock after purchasing an additional 15,964 shares during the period. Cetera Investment Advisers’ holdings in Takeda Pharmaceutical were worth $1,119,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently bought and sold shares of the stock. Vise Technologies Inc. raised its position in Takeda Pharmaceutical by 3.1% in the 4th quarter. Vise Technologies Inc. now owns 34,635 shares of the company’s stock valued at $459,000 after purchasing an additional 1,026 shares in the last quarter. Farther Finance Advisors LLC lifted its stake in Takeda Pharmaceutical by 29.2% during the first quarter. Farther Finance Advisors LLC now owns 4,620 shares of the company’s stock worth $69,000 after purchasing an additional 1,045 shares during the last quarter. Allspring Global Investments Holdings LLC lifted its stake in Takeda Pharmaceutical by 5.4% during the first quarter. Allspring Global Investments Holdings LLC now owns 21,373 shares of the company’s stock worth $319,000 after purchasing an additional 1,098 shares during the last quarter. Allworth Financial LP lifted its stake in Takeda Pharmaceutical by 12.7% during the first quarter. Allworth Financial LP now owns 10,797 shares of the company’s stock worth $163,000 after purchasing an additional 1,215 shares during the last quarter. Finally, Choreo LLC lifted its stake in Takeda Pharmaceutical by 6.1% during the first quarter. Choreo LLC now owns 21,262 shares of the company’s stock worth $316,000 after purchasing an additional 1,229 shares during the last quarter. Institutional investors and hedge funds own 9.17% of the company’s stock.

Takeda Pharmaceutical Trading Down 0.1%

NYSE TAK opened at $14.43 on Tuesday. The company has a debt-to-equity ratio of 0.60, a current ratio of 1.16 and a quick ratio of 0.59. The firm’s fifty day moving average price is $14.81 and its 200 day moving average price is $14.59. The company has a market capitalization of $45.90 billion, a price-to-earnings ratio of 48.08 and a beta of 0.22. Takeda Pharmaceutical Co. has a 12 month low of $12.80 and a 12 month high of $15.53.

Takeda Pharmaceutical (NYSE:TAK) last posted its earnings results on Wednesday, July 30th. The company reported $0.52 EPS for the quarter, beating analysts’ consensus estimates of $0.47 by $0.05. The firm had revenue of $7.45 billion for the quarter, compared to the consensus estimate of $7.96 billion. Takeda Pharmaceutical had a net margin of 3.20% and a return on equity of 10.50%. On average, sell-side analysts expect that Takeda Pharmaceutical Co. will post 1.64 earnings per share for the current fiscal year.

Takeda Pharmaceutical Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.